- Email: [email protected]
Special volume “Chronic Lymphocytic Leukemia”
Best Practice & Research Clinical Haematology xxx (2016) 1
Contents lists available at ScienceDirect
Best Practice & Research Clinical Haematology journal homepage: www.elsevier.com/locate/beha
Preface
Special volume “Chronic Lymphocytic Leukemia”
During the last five years we have seen the emergence of biological and targeted therapies for chronic lymphocytic leukemia (CLL) like never before. Gradually the use of chemo-immunotherapy regimens is becoming less frequent by clinicians and the expectations of patients regarding targeted therapies are increasing in parallel with a record number of approvals by the FDA. For this especial volume in CLL, a highly selected group of world experts were invited to participate, and I am very grateful for their participation and time. Especially, I feel very proud and honored to have the participation of two CLL patients that are leaders in patient advocacy. They wrote a chapter discussing the CLL patient's perspective and how they see from their particular angle the exciting scientific and clinical developments in the field and the contrast between great news and confusing news that regularly patient go through whenever important medical decisions need to be made. Together with the invited authors, we concentrated our efforts in selecting some of the most active topics that are relevant to both physicians and patients: For example we will review basic concepts related to the leukemia cell microenvironment and prognostic markers, the biology of genetic evolution in CLL and implications of high risk cytogenetics such as 17pDeletion in the prognosis and treatment selection. We incorporated a risk adapted review of the clinical management of CLL in the era of biological targeted therapy, the biology and clinical implications of Richter's syndrome and the potential use of hematopoietic stem cell transplantation in this condition and other subsets of patients with high-risk CLL. In addition, we have incorporated a discussion on personalized medicine in CLL alone with reviews on the clinical use of targeted therapies particularly B cell receptor and Bcl-2 inhibitors, which are the latest therapies approved by the FDA. Lastly, we also present here a review on the current status of adoptive cellular therapy using engineered immune cells. We hope you find the chapters of interest. Conflict of interest No conflict of interest. Januario E. Castro, M.D., Professor of Medicine Moores e Cancer Center, University of California San Diego, La Jolla, CA, USA E-mail address: [email protected]
http://dx.doi.org/10.1016/j.beha.2016.08.012 1521-6926/© 2016 Elsevier Ltd. All rights reserved.
Please cite this article in press as: Castro JE, Special volume “Chronic Lymphocytic Leukemia”, Best Practice & Research Clinical Haematology (2016), http://dx.doi.org/10.1016/j.beha.2016.08.012
Contents lists available at ScienceDirect
Best Practice & Research Clinical Haematology journal homepage: www.elsevier.com/locate/beha
Preface
Special volume “Chronic Lymphocytic Leukemia”
During the last five years we have seen the emergence of biological and targeted therapies for chronic lymphocytic leukemia (CLL) like never before. Gradually the use of chemo-immunotherapy regimens is becoming less frequent by clinicians and the expectations of patients regarding targeted therapies are increasing in parallel with a record number of approvals by the FDA. For this especial volume in CLL, a highly selected group of world experts were invited to participate, and I am very grateful for their participation and time. Especially, I feel very proud and honored to have the participation of two CLL patients that are leaders in patient advocacy. They wrote a chapter discussing the CLL patient's perspective and how they see from their particular angle the exciting scientific and clinical developments in the field and the contrast between great news and confusing news that regularly patient go through whenever important medical decisions need to be made. Together with the invited authors, we concentrated our efforts in selecting some of the most active topics that are relevant to both physicians and patients: For example we will review basic concepts related to the leukemia cell microenvironment and prognostic markers, the biology of genetic evolution in CLL and implications of high risk cytogenetics such as 17pDeletion in the prognosis and treatment selection. We incorporated a risk adapted review of the clinical management of CLL in the era of biological targeted therapy, the biology and clinical implications of Richter's syndrome and the potential use of hematopoietic stem cell transplantation in this condition and other subsets of patients with high-risk CLL. In addition, we have incorporated a discussion on personalized medicine in CLL alone with reviews on the clinical use of targeted therapies particularly B cell receptor and Bcl-2 inhibitors, which are the latest therapies approved by the FDA. Lastly, we also present here a review on the current status of adoptive cellular therapy using engineered immune cells. We hope you find the chapters of interest. Conflict of interest No conflict of interest. Januario E. Castro, M.D., Professor of Medicine Moores e Cancer Center, University of California San Diego, La Jolla, CA, USA E-mail address: [email protected]
http://dx.doi.org/10.1016/j.beha.2016.08.012 1521-6926/© 2016 Elsevier Ltd. All rights reserved.
Please cite this article in press as: Castro JE, Special volume “Chronic Lymphocytic Leukemia”, Best Practice & Research Clinical Haematology (2016), http://dx.doi.org/10.1016/j.beha.2016.08.012